Literature DB >> 8750263

Allogeneic bone marrow transplantation for primary myelofibrosis.

S Singhal1, R Powles, J Treleaven, C Pollard, H Lumley, J Mehta.   

Abstract

The published experience of allogeneic bone marrow transplantation for primary myelofibrosis (PMF) is limited. Three patients (24-49 years) with PMF received allogeneic marrow grafts from HLA-identical sibling donors after conditioning with 110 mg/m2 melphalan and 1050 cGy total-body irradiation (TBI). Donor marrow was not depleted of T cells, and graft-versus-host disease (GVHD) prophylaxis comprised cyclosporine and methotrexate. None of the patients was splenectomized prior to the transplant. Two patients received G-CSF post-transplant to hasten neutrophil recovery. One patient died of multi-organ failure 23 days post-transplant. Hematopoietic recovery was relatively slow in the other two who had gradual resolution of the marrow fibrosis over several months. One of the two died of overwhelming pneumococcal sepsis within 2 weeks of stopping prophylactic penicillin 31 months post-transplant. The other patient is alive and well 20 months post-transplant with a Karnofsky score of 100% and no fibrosis of the marrow. We conclude that PMF is correctable by allogeneic BMT. Hematologic recovery post-transplant is slow, but counts may normalize with time without the need for splenectomy.

Entities:  

Mesh:

Year:  1995        PMID: 8750263

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  1 in total

1.  Primary myelofibrosis terminated in basophilic leukemia and successful allogeneic bone marrow transplantation.

Authors:  Naoshi Sugimoto; Takayuki Ishikawa; Saori Gotoh; Isaku Shinzato; Akiko Matsushita; Kenichi Nagai; Noriko Ohgoh; Takayuki Takahashi
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.